Meta Platforms, Inc.

(NASDAQ Global Select)
Neutral +5

Top Analyst Reports for Meta, Pfizer & Salesforce

๐Ÿ“‰ Meta Platforms shares have declined -7.9% over the past year, trailing its Internet-Software industry peer group's decline of -16.2%.

โš ๏ธ Cost inflation in AI infrastructure and ongoing losses from Reality Labs are key challenges facing Meta according to analysts.

๐Ÿ”ฌ Meta is extending its AI capabilities across Facebook, Instagram, WhatsApp, and Threads while upgrading recommendation engines.

๐Ÿ“ˆ Pfizer's shares have gained +25.9% this year, outperforming the Large Cap Pharmaceuticals industry which rose 29.9%.

๐Ÿ’Š Pfizer beat first-quarter earnings estimates but faces patent expirations for key drugs between 2026 and 2030.

๐Ÿ”ฎ Company guidance indicates flat to slightly negative revenue growth in 2026 as it rebuilds its oncology and obesity pipelines.

๐Ÿ“‰ Salesforce stock has underperformed the industry by 25.5% over the past year due to competition and currency fluctuations.

๐Ÿ’ป Salesforce is driving top-line growth through customer digital transformation and continued international deal wins.

๐Ÿค– Generative AI expansion and partnerships with Amazon and Alphabet are key strategic moves for the enterprise software provider.

๐Ÿ—๏ธ Smith-Midland, a micro-cap stock, underperformed its Building Products industry by 17% while facing infrastructure demand tailwinds.

๐Ÿ’ฐ Barrier rental revenues at Smith-Midland surged 88% year over-year despite Q3 normalization effects.

๐Ÿ“ฆ The company saw significant growth in proprietary products like SlenderWall (+$1.1M), soundwalls (+52%), and modular buildings (+50%).

๐Ÿ’น Smith-Midland maintained resilient margins at 26.8% and holds a $54.8-million backlog to support 2026 growth visibility.

๐Ÿ” Zacks Research released daily reports on 16 major stocks, including other notables like ConocoPhillips and Rockwell Automation.

๐Ÿ“ฐ The 'Ahead of Wall Street' article provides pre-market analysis of economic releases impacting daily trading action.

Bullish Signals
  • Meta's latest quarter shows that recommendation upgrades and advertiser tools are lifting engagement and ad efficiency.
  • Management is extending AI deeper across Facebook, Instagram, WhatsApp, and Threads while building frontier models to expand monetization in messaging, commerce, and creator tools.
  • Smart glasses add another product vector for Meta as it continues to lean into a multi-year buildout of frontier models and data center capacity.
  • Pfizer beat first-quarter estimates for earnings and sales despite previous declines driven by COVID-related product sales.
  • Pfizer's non-COVID operational revenues are improving, driven by key products like Vyndaqel, Padcev, and Eliquis, along with new launches and acquired products.
  • Salesforce is benefiting from a robust demand environment as customers undergo a major digital transformation, driving the top line.
  • Continued deal wins in the international market are serving as another growth driver for Salesforce.
  • Acquisitions including Slack, Informatica, Waii, and Convergence.ai have broadened Salesforce's portfolio and improved competitiveness against enterprise software providers.
  • Salesforce's strategy of continuous expansion of generative AI offerings will help it tap the growing opportunities in the space.
  • Smith-Midland's nine-month rental revenues surged 88% year over year, benefiting from high utilization and margin-accretive MASH-compliant fleets.
  • Smith-Midland's new product lines contributed significantly to Q3 with Proprietary SlenderWall contributing $1.1 million after no prior-year sales.
  • Soundwalls grew 52% year over year at Smith-Midland while Easi-Set modular buildings rose 50% year over year, capturing public and infrastructure projects.
  • Smith-Midland's margins stayed resilient at 26.8% with disciplined cost control, supported by a strong balance sheet for continued investment.
Risk Factors
  • Meta shares have declined -7.9% over the past year, outperforming less negatively than the Zacks Internet - Software industry's decline of -16.2%.
  • The company is facing significant headwinds including cost inflation in AI infrastructure pushing spending higher and Reality Labs remaining loss-generating.
  • Regulatory and litigation scrutiny remains elevated overall for Meta, posing potential financial and operational risks.
  • Payoff from Meta AI and agents is still developing, introducing uncertainty regarding near-term revenue contributions from these strategic initiatives.
  • Management is committing to a multi-year buildout of frontier models and supporting data center capacity with higher infrastructure spending, which could strain cash flow.
  • Salesforce shares have significantly underperformed the industry with a -41.7% drop compared to the -16.2% industry decline.
  • Salesface faces stiff competition and unfavorable currency fluctuations which are cited as specific concerns impacting its financial performance.
  • A challenging macroeconomic environment could hurt Salesforce's growth prospects, potentially delaying recovery or expansion.
Full Analysis
Zacks Research Daily published a research update on Wednesday, May 13, 2026, featuring analyst reports for Meta Platforms (META), Pfizer (PFE), Salesforce (CRM), and micro-cap Smith-Midland Corp (SMID). The article notes that META shares have declined 7.9% over the past year, underperforming the broader Zacks Internet - Software industry which is down 16.2%. Analysts attribute this underperformance to rising cost inflation in AI infrastructure, persistent losses in Reality Labs, and elevated regulatory scrutiny. However, the report highlights that Meta is deepening its AI integration across Facebook, Instagram, WhatsApp, and Threads, with recent quarter data suggesting that recommendation upgrades and new advertiser tools are improving engagement and ad efficiency. Management remains committed to a multi-year buildout of frontier models and supporting data center capacity to maintain the core ads engine while expanding monetization in messaging and commerce, alongside the rollout of smart glasses as a new product vector. Regarding Pfizer, shares have gained 25.9% over the past year, outpacing the industry average which is up 29.9%. The company recently beat first-quarter estimates for both earnings and sales following a three-year period hampered by a sharp decline in COVID-related product revenue. Non-COVID operational revenues are recovering through key products like Vyndaqel, Padcev, and Eliquis, as well as new launches and acquired assets. Challenges remain regarding upcoming patent expirations on major drugs scheduled for 2026-2030, which could pressure growth, yet the company expects new and acquired products to partially offset these losses. Pfizer is also rebuilding its pipeline in oncology and obesity with expectations of driving growth starting in 2028, and it has provided revenue guidance for 2026 indicating mostly flat to slightly negative growth. For Salesforce (CRM), shares have significantly underperformed the Zacks Internet - Software industry over the past year, dropping 41.7% compared to the sector's decline of 16.2%. The primary concerns cited are stiff market competition and unfavorable currency fluctuations within a challenging macroeconomic environment that could impact future growth. Despite these headwinds, the report points to a robust demand environment as customers undergo major digital transformations, aligning products with customer needs has driven top-line growth, and continued deal wins in international markets serve as a growth driver. Acquisitions such as Slack, Informatica, Waii, and Convergence.ai have broadened the portfolio to compete better against enterprise software providers, while partnerships with Amazon and Alphabet aid international expansion. Salesforceโ€™s strategy of continuously expanding its generative AI offerings aims to capitalize on growing opportunities in that specific space. Finally, the report covers Smith-Midland (SMID), a micro-cap company with a market capitalization of approximately $163.23 million, which has underperformed its Building Products - Concrete and Aggregates industry sector. The investment case centers on a shift toward higher-margin, recurring, and asset-light revenue streams supported by infrastructure demand. Barrier rentals are identified as the core growth driver, with nine-month rental revenues surging 88% year over year, aided by high utilization and margin-accretive MASH-compliant fleets. Specific product lines including Proprietary SlenderWall contributed $1.1 million in Q3 after no prior-year sales, soundwall growth rose 52% year over year, and Easi-Set modular buildings grew 50% year over year capturing public and infrastructure projects. Margins remained resilient at 26.8% due to disciplined cost control, a strong balance sheet supports investment, and a $54.8-million backlog combined with government infrastructure tailwinds provides visibility into growth for 2026.